About This Atlas

What this atlas charts

Peptide Mundo charts the published research on three incretin-class peptides studied for metabolic regulation and weight management: semaglutide, tirzepatide, and retatrutide, with tirzepatide as the anchor of the map. A field this crowded — and this often overstated — needs a legible chart, so each route through the literature is drawn in plain language with a citation at every turn: what each compound was actually studied for, in which populations, and how far that evidence honestly reaches.

The map is laid out along the incretin agonism ladder: three compounds that progressively engage one, two, and three metabolic receptors. Traced together they show more than any single route can — what the GLP-1 arm contributes, what adding GIP changes, and what the glucagon arm brings (along with what about it is still uncharted). Each compound holds its own page; a comparison page lays them side by side; and one shared reference list gathers every source drawn on across the three.

Two of the three — semaglutide and tirzepatide — are approved prescription medicines backed by large, rigorous trial programs. The third, retatrutide, is still investigational. All three are charted to the same standard: what was studied, how, in whom, and what was found — with a firm line drawn between an FDA-approved indication and a Phase 2 signal from a 338-person trial. Holding that line is the whole reason the atlas exists.

How the map is drawn

Three rules govern where the ink goes.

Every route traces back to the peer-reviewed record. Each factual statement carries a numbered citation — PubMed-indexed articles, clinical-trial publications, and peer-reviewed reviews, with DOIs and PubMed links — gathered on the references page. Where a point comes from a review rather than a primary study, the map marks it as such.

Terrain is drawn to scale. Findings are reported in the populations and conditions in which they were actually studied — the SURMOUNT-5 result, for one, is charted as a 72-week head-to-head trial in 751 adults with obesity, not a universal law. Where a finding is Phase 2 only, or preclinical, or pulled from a pharmacovigilance database rather than a controlled trial, the page says so; where two sources disagree or a signal is unconfirmed, both bearings are shown.

The three routes connect. Because the same features — incretin receptor signaling, appetite suppression, GI motility, gallbladder risk, lean-mass loss — recur across all three compounds, the pages cross-link to each other and to the comparison, so a reader can follow one theme clear across the atlas.

The edges of the map

A map is not the territory, and this one has firm edges. Peptide Mundo is no pharmacy, clinic, telehealth platform, or vendor of any kind. Nothing here is sold, supplied, sourced, or brokered — no medicine, no research chemical — and no pharmaceutical company, telehealth provider, or chemical supplier pays for a place on the page. No clinician is on staff; nothing is diagnosed and nothing is prescribed, and no dose, schedule, or route is named for any person.

Semaglutide and tirzepatide are approved prescription medicines, reachable only through licensed providers. Retatrutide is not approved and belongs to the setting of registered clinical trials. Anyone seeking clinical guidance should take it to a licensed provider in their own jurisdiction, working from regulated, evidence-based options fitted to their situation. Notes on citation fixes, stale references, or newly published studies are welcome by way of the contact page; that mail is read with care, but requests for medical advice cannot be answered.